Live Breaking News & Updates on மூலக்கூறு புற்றுநோய் மருந்தியல்

Exact Therapeutics Abstract on its Phase I ACTIVATE Study to be Presented at the 2021 ASCO Annual Meeting
News provided by
Share this article
Share this article
OSLO, Norway and LONDON, May 20, 2021 /PRNewswire/  Exact Therapeutics AS (Euronext Growth: EXTX), a clinical stage precision medicine company utilizing Acoustic Cluster Therapy (ACT®) to harness the power of ultrasound in therapeutic amplification across multiple therapeutic areas and product classes, today announces that an abstract describing the background and methodology of its Phase I study, ACTIVATE, has been released for publication at the 2021 ASCO Annual Meeting.
The ACTIVATE Study (NCT04021277) is the first in a series of clinical investigations planned of the Company s Acoustic Cluster Therapy (ACT®) platform technology for targeted therapeutic enhancement. ....

City Of , United Kingdom , Udai Banerji , Institute Of Cancer Research , Company Acoustic Cluster Therapy , Exact Therapeutics , Euronext Growth , Acoustic Cluster Therapy , Abstract Session , Developmental Therapeutics , Molecularly Targeted Agents , Tumor Biology , Professor Udai Banerji , Molecular Cancer Pharmacology , Cancer Research , Honorary Consultant , Medical Oncology , Royal Marsden , நகரம் ஆஃப் , ஒன்றுபட்டது கிஂக்டம் , உதாய் பானெர்ஜி , நிறுவனம் ஆஃப் புற்றுநோய் ஆராய்ச்சி , சரியான சிகிச்சை , ஒலி கொத்து சிகிச்சை , வளர்ச்சி சிகிச்சை , கட்டி உயிரியல் ,